未登录

P

Po-Lin Tseng

chang gung memorial hospital

H指数:24

被引数:1,546

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Hepatitis B relapse after entecavir or tenofovir alafenamide cessation under anti-viral prophylaxis for cancer chemotherapy

VIROLOGY JOURNAL

IF3.8

2024-04-030

OAAI

A novel evidence of serial changes of bone mineral density in chronic hepatitis B patients treated with entecavir

HEPATOLOGY INTERNATIONAL

IF6.1

2021-04-277

PREAI

Five-year comparative risk of hepatocellular carcinoma development under entecavir or tenofovir treatment-naive patients with chronic hepatitis B-related compensated cirrhosis in Taiwan

ALIMENTARY PHARMACOLOGY & THERAPEUTICS

IF6.7

2020-10-2720

PREAI

Role of hepatitis B surface antigen in hepatitis B virus relapse after entecavir or tenofovir prophylaxis in patients undergoing cancer chemotherapy

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

IF3.4

2018-04-1710

PREAI

Comparisons the durability of 6 months and 12 months prolonged treatment duration after cessation chemotherapy in chronic hepatitis B patients with prophylaxis antiviral therapy: A open level randomized clinical trial

JOURNAL OF HEPATOLOGY

IF33

2018-04-010

PREAI

Decreased succinate dehydrogenase B in human hepatocellular carcinoma accelerates tumor malignancy by inducing the Warburg effect

SCIENTIFIC REPORTS

IF3.9

2018-02-1577

OAAI

The association between steatosis and diabetes with hepatocellular carcinoma in non-genotype 3 chronic hepatitis C patients

LIVER INTERNATIONAL

IF5.2

2017-12-1217

PREAI

A Randomized Controlled Trial of Glycyrrhizin Plus Tenofovir vs. Tenofovir in Chronic Hepatitis B with Severe Acute Exacerbation

CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY

IF3

2017-06-0122

OAAI

Transient elastography as a screening tool for liver fibrosis in a large hemodialysis population

SCIENTIFIC REPORTS

IF3.9

2017-04-199

OAAI

MicroRNA-122 as a predictor of HBsAg seroclearance in hepatitis B and C dual infected patients treated with interferon and ribavirin

SCIENTIFIC REPORTS

IF3.9

2016-09-2610

OAAI

Three-year efficacy and safety of tenofovir in nucleos(t)ide analog-naive and nucleos(t)ide analog-experienced chronic hepatitis B patients

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

IF3.4

2016-07-2723

PREAI

Comparison of renal safety and efficacy of telbivudine, entecavir and tenofovir treatment in chronic hepatitis B patients: real world experience

CLINICAL MICROBIOLOGY AND INFECTION

IF8.5

2016-01-0154

OAAI

PTEN EXPRESSION AFFECTS OUTCOME OF HUMAN HEPATOCELLULAR CARCINOMA VIA MODULATION OF THE ONCOGENIC PHENOTYPES AND ANGIOGENIC PROCESSES

EUROPEAN JOURNAL OF CANCER

IF7.1

2015-07-010

PREAI

A Polymorphism in Interferon L3 Is an Independent Risk Factor for Development of Hepatocellular Carcinoma After Treatment of Hepatitis C Virus Infection

CLINICAL GASTROENTEROLOGY AND HEPATOLOGY

IF12

2015-05-0150

OAAI

A POLYMORPHISM IN IFNL3 IS AN INDEPENDENT RISK FACTOR FOR DEVELOPMENT OF HEPATOCELLULAR CARCINOMA AFTER TREATMENT OF HCV INFECTION

JOURNAL OF HEPATOLOGY

IF33

2015-04-010

PREAI

The validation of the 2010 American Association for the Study of Liver Diseases guideline for the diagnosis of hepatocellular carcinoma in an endemic area

美国2010肝病研究协会指南对流行地区肝细胞癌诊断的有效性

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

IF3.4

2015-01-246

PREAI

Entecavir vs. lamivudine in chronic hepatitis B patients with severe acute exacerbation and hepatic decompensation

JOURNAL OF HEPATOLOGY

IF33

2014-06-0154

PREAI

THE CLINICAL-GUIDE RISK PREDICTION MODEL OF HEPATOCELLULAR CARCINOMA DEVELOPMENT IN CHRONIC HEPATITIS C PATIENTS AFTER INTERFERON-BASED THERAPY

JOURNAL OF HEPATOLOGY

IF33

2014-04-010

PREAI

Comparing the efficacy and clinical outcome of telbivudine and entecavir naive patients with hepatitis B virus-related compensated cirrhosis

JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY

IF3.4

2014-02-1920

PREAI

A comparison of efficacy and safety of 2-year telbivudine and entecavir treatment in patients with chronic hepatitis B: a match-control study

CLINICAL MICROBIOLOGY AND INFECTION

IF8.5

2014-02-0128

OAAI